Tocilizumab

Tocilizumab Reactions 1680, p323 - 2 Dec 2017 Nodular scleritis: case report A 48-year-old woman developed anterior nodular scleritis following initiation of tocilizumab therapy for rheumatoid arthritis (RA). The woman had a history of RA, pyoderma gangrenosum, and systemic lupus erythematosus. Although, she had been treated with rituximab, methotrexate, sulfasalazine, hydroxychloroquine, and folic acid, her RA remained in active state. Therefore, her treatment was changed to IV tocilizumab 8 mg/kg every four weeks. Rituximab and methotrexate were discontinued prior to initiating tocilizumab. After the first dose of tocilizumab, clinical remission of her RA was noted, with a 28 joint Disease Activity Score of 2.41 as compared to previous score of 6.28. Additionally, the CRP decreased to < 1 from 28. Emergence of a lesion in an eye was noted subsequent to the second dose of tocilizumab. The lesion was diagnosed as nodular scleritis and the woman was treated with tapering dose of prednisone with clinical response. Tocilizumab was discontinued simultaneously and complete resolution of the nodular lesion was noted at nine months, without steroids. No other signs of intraocular inflammation were noted on ophthalmological examination using the slit-lamp. A tuberculosis blood test, full blood count and Treponema screen were performed to exclude infectious aetiology. It was postulated that this was a paradoxical effect of the tocilizumab treatment, provided that she had no previous incident of extra-articular manifestations, her inflammatory profile was suppressed, and considering the temporal relationship with initiation of tocilizumab. The woman did not accept the offer for tocilizumab re- challenge. Author comment: "[Tocilizumab] is an anti–IL-6 receptor monoclonal antibody, thereby conferring its antiinflammatory properties through this mechanism." "We conclude that ocular manifestations as a result of IL-6 inhibition should be considered as a possible paradoxical phenomenon when treating inflammatory arthritis." Michael E, et al. Paradoxical nodular scleritis during tocilizumab therapy: A case report. The Journal of Rheumatology 44: 1760-1761, No. 11, 01 Nov 2017. Available from: URL: http://doi.org/10.3899/jrheum.170234 - New Zealand 803285040 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Tocilizumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/tocilizumab-eYo8i35VUp
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39254-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p323 - 2 Dec 2017 Nodular scleritis: case report A 48-year-old woman developed anterior nodular scleritis following initiation of tocilizumab therapy for rheumatoid arthritis (RA). The woman had a history of RA, pyoderma gangrenosum, and systemic lupus erythematosus. Although, she had been treated with rituximab, methotrexate, sulfasalazine, hydroxychloroquine, and folic acid, her RA remained in active state. Therefore, her treatment was changed to IV tocilizumab 8 mg/kg every four weeks. Rituximab and methotrexate were discontinued prior to initiating tocilizumab. After the first dose of tocilizumab, clinical remission of her RA was noted, with a 28 joint Disease Activity Score of 2.41 as compared to previous score of 6.28. Additionally, the CRP decreased to < 1 from 28. Emergence of a lesion in an eye was noted subsequent to the second dose of tocilizumab. The lesion was diagnosed as nodular scleritis and the woman was treated with tapering dose of prednisone with clinical response. Tocilizumab was discontinued simultaneously and complete resolution of the nodular lesion was noted at nine months, without steroids. No other signs of intraocular inflammation were noted on ophthalmological examination using the slit-lamp. A tuberculosis blood test, full blood count and Treponema screen were performed to exclude infectious aetiology. It was postulated that this was a paradoxical effect of the tocilizumab treatment, provided that she had no previous incident of extra-articular manifestations, her inflammatory profile was suppressed, and considering the temporal relationship with initiation of tocilizumab. The woman did not accept the offer for tocilizumab re- challenge. Author comment: "[Tocilizumab] is an anti–IL-6 receptor monoclonal antibody, thereby conferring its antiinflammatory properties through this mechanism." "We conclude that ocular manifestations as a result of IL-6 inhibition should be considered as a possible paradoxical phenomenon when treating inflammatory arthritis." Michael E, et al. Paradoxical nodular scleritis during tocilizumab therapy: A case report. The Journal of Rheumatology 44: 1760-1761, No. 11, 01 Nov 2017. Available from: URL: http://doi.org/10.3899/jrheum.170234 - New Zealand 803285040 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off